Summary: For patients with acute stroke or transient ischemic attack (TIA), use of aspirin as antiplatelet therapy for secondary prevention appears to be associated with the same rate of stroke, myocardial infarction, or death over the next 90 days as is the use of ticagrelor, but at potentially much lower cost.

Strength of Recommendation = B